{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T01:39:16Z","timestamp":1774661956680,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"309 Hospital","award":["2016ZD-007"],"award-info":[{"award-number":["2016ZD-007"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jocn.2019.02.012","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T22:50:56Z","timestamp":1551480656000},"page":"32-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Elevated expression of interleukin-33 in myasthenia gravis patients"],"prefix":"10.1016","volume":"63","author":[{"given":"Zhongkui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xusheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2019.02.012_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2019.02.012_b0010","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1172\/JCI2068","article-title":"A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes","volume":"101","author":"Nagvekar","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocn.2019.02.012_b0015","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: A comprehensive review of immune dysregulationand etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jocn.2019.02.012_b0025","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.4049\/jimmunol.178.11.7072","article-title":"C57BL\/6 mice genetically deficient in IL-12\/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells","volume":"178","author":"Wang","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0030","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2019.02.012_b0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2015.07.013","article-title":"Increased serum peroxiredoxin 5 levels in myasthenia gravis","volume":"287","author":"Uzawa","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2019.02.012_b0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2016.05.004","article-title":"Interleukin-33, friend and foe in type-2 immune responses","volume":"42","author":"Hardman","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.rbr.2016.01.006","article-title":"IL33 in rheumatoid arthritis: potential contribution to pathogenesis","volume":"56","author":"Macedo","year":"2016","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"10.1016\/j.jocn.2019.02.012_b0065","first-page":"16000","article-title":"Serum Interleukin-33 level in Saudi children with inflammatory bowel disease","volume":"8","author":"Saadah","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jocn.2019.02.012_b0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1620\/tjem.234.255","article-title":"Interleukin-33 promotes disease progression in patients with primary biliary cirrhosis","volume":"234","author":"Sun","year":"2014","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.jocn.2019.02.012_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.12.015","article-title":"What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?","volume":"315","author":"Rozmilowska","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2019.02.012_b0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1590\/0004-282x20170075","article-title":"Quantitative Myasthenia Gravis Score: a Brazilian multicenter study for translation, cultural adaptation and validation","volume":"75","author":"Oliveira","year":"2017","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jocn.2019.02.012_b0090","doi-asserted-by":"crossref","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in inflammatory cytokine networks in myasthenia gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jocn.2019.02.012_b0095","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature13577","article-title":"The alarmin IL-33 promotes regulatory T-cell function in the intestine","volume":"513","author":"Schiering","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2019.02.012_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/587376","article-title":"Role of IL-33 and its receptor in T cell-mediated autoimmune diseases","volume":"2014","author":"Zhao","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jocn.2019.02.012_b0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2017.07.022","article-title":"IL-33-matured dendritic cells promote Th17 cell responses via IL-1\u03b2 and IL-6","volume":"99","author":"Park","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jocn.2019.02.012_b0110","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.4049\/jimmunol.179.2.1080","article-title":"TLR3- and Th2 cytokine- dependent production of thymic stromal lymphopoietin in human airway epithelial cells","volume":"179","author":"Kato","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0115","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20101876","article-title":"Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer","volume":"208","author":"De Monte","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2019.02.012_b0125","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/rheumatology\/kev241","article-title":"Thymic stromal lymphopoietin as a novel mediator amplifying immunopathology in rheumatic disease","volume":"54","author":"Hillen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jocn.2019.02.012_b0130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/ni1360","article-title":"Thymic stromal lymphopoietin in normal and pathogenic T cell development and function","volume":"7","author":"Ziegler","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cei.12621","article-title":"Thymic stromal lymphopoietin deficiency attenuates experimental autoimmune encephalomyelitis","volume":"181","author":"Eckhardt","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130830","article-title":"The additive inflammatory in vivo and in vitro effects of IL-7 and TSLP in arthritis underscore the therapeutic rationale for dual blockade","volume":"10","author":"Hillen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2019.02.012_b0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jneuroim.2015.08.013","article-title":"Aberrant decrease of microRNA19b regulates TSLP expression and contributes to Th17 cells development in myasthenia gravis related thymomas","volume":"288","author":"Wang","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2019.02.012_b0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mi.2011.64","article-title":"Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis","volume":"5","author":"Spadoni","year":"2012","journal-title":"Mucosal Immunol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818315546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818315546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:17:29Z","timestamp":1760822249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818315546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"alternative-id":["S0967586818315546"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2019.02.012","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated expression of interleukin-33 in myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2019.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}